Ostatní
Návod 
Alnylam Pharmaceuticals, Inc.
ALNY
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
59.1B
Obrat
4B
Zisk
0B
Aktiva
5B
Dluh
3B
ROE
0%
ROA
0%
PE
136
PS
11
Cena 1R
206-496
⌀ Cena
377.68
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
12-02-2026
Poslední dividenda
Profil
Alnylam Pharmaceuticals, Inc., biofarmaceutická společnost, se zaměřuje na objevování, vývoj a komercializaci nových léčebných postupů založených na interferenci ribonukleové kyseliny. Příprava výzkumné RNAi terapie se zaměřuje na genetické léky, kardio-metabolické choroby, jaterní infekční onemocnění a centrální nervový systém (CNS)/oční onemocnění. Mezi produkty uváděné na trh patří ONPATTRO (patisiran), injekce obsahující lipidy určená k léčbě polyneuropatie dědičné amyloidózy zprostředkované transthyretinem u dospělých, GIVLAARI k léčbě dospělých s akutní jaterní porfyrií (AHP) a OXLUMO (lumasiran) k léčbě primární hyperoxalurie typu 1 (PH1). Společnost dále vyvíjí givosiran pro léčbu dospívajících pacientů s AHP; patisiran pro léčbu amyloidózy transthyretinu nebo ATTR amyloidózy s kardiomyopatií; cemdisiran pro léčbu onemocnění vyvolaných komplementem; ALN-AAT02 pro léčbu onemocnění jater spojených s nedostatkem AAT; ALN-HBV02 pro léčbu chronické infekce HBV; zilebesiran pro léčbu hypertenze a ALN-HSD pro léčbu NASH. Dále nabízí Fitusiran k léčbě hemofilie a vzácných krvácivých poruch, Inclisiran k léčbě hypercholesterolemie, lumasiran k léčbě pokročilého PH1 a rekurentních ledvinových kamenů a vutrisiran k léčbě ATTR amyloidózy, která je součástí klinické studie fáze 3. Společnost Alnylam Pharmaceuticals, Inc. spolupracuje se společností Regeneron Pharmaceuticals, Inc. na objevování, vývoji a komercializaci RNAi terapií pro řadu onemocnění tím, že se zaměřuje na terapeutické cíle vyjádřené v oku a CNS; a Sanofi Genzyme na objevování, vývoj a komercializaci RNAi terapií. Společnost má také licenční smlouvy a smlouvy o spolupráci se společnostmi Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc. a PeptiDream, Inc. Společnost byla založena v roce 2002 a sídlí v Cambridge ve státě Massachusetts.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
2230
Založení
2004-06-01
Podobné společnosti
$ 863.20
+ $ 8.55
$ 660.00
+ $ 2.47
$ 700.73
- $ 7.72
$ 177.84
- $ 0.07
$ 119.67
- $ 0.57
$ 83.48
+ $ 0.09
$ 294.08
- $ 0.79
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 3,713.9 | 3,713.9 | 2,248.2 | 1,828.3 | 1,037.4 | 844.3 | 492.9 | 219.8 | 74.9 | 89.9 | 47.2 | 41.1 | 50.6 | 47.2 | 66.7 | 82.8 | 100.0 | |
| Cost of Revenues | 678.9 | 677.2 | 323.4 | 310.4 | 168.8 | 140.1 | 78.1 | 25.1 | 1.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | 3,035.0 | 3,036.8 | 1,924.9 | 1,517.9 | 868.6 | 704.1 | 414.8 | 194.7 | 73.1 | 89.9 | 47.2 | 41.1 | 50.6 | 47.2 | 66.7 | 82.8 | 100.0 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 1,097.0 | 1,249.0 | 773.7 | 594.2 | 593.2 | 500.9 | 659.8 | 494.3 | 439.7 | 750.5 | |
| Cost of Revenues | 267.7 | 197.2 | 143.0 | 71.0 | 102.8 | 85.9 | 68.7 | 66.0 | 85.9 | 84.3 | |
| Gross Profit | 829.3 | 1,051.8 | 630.7 | 523.1 | 490.3 | 415.0 | 591.2 | 428.4 | 353.9 | 666.2 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 1,004.4 | 883.0 | 792.2 | 654.8 | 655.1 | 505.4 | 390.6 | 382.4 | 276.5 | 190.2 | 113.0 | 86.6 | 99.3 | 106.4 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 795.6 | 770.7 | 620.6 | 588.4 | 479.0 | 382.4 | 199.4 | 89.4 | 60.6 | 44.5 | 27.2 | 44.6 | 38.3 | 37.7 | |
| Depreciation & Amortization | 55.7 | 55.7 | 56.7 | 54.1 | -109.4 | -0.5 | 57.3 | 54.4 | 6.4 | 13.4 | 15.1 | 19.1 | 11.9 | 10.2 | 9.0 | 5.1 | 4.9 | |
| Total Operating Expenses | 2,533.4 | 2,535.2 | 2,101.8 | 1,800.1 | 1,653.7 | 1,412.8 | 1,243.2 | 1,134.1 | 887.8 | 590.0 | 471.7 | 337.1 | 234.8 | 140.1 | 131.2 | 137.6 | 144.1 | |
| Operating Income | 501.6 | 501.6 | -176.9 | -282.2 | -785.1 | -708.7 | -828.4 | -939.4 | -814.7 | -500.1 | -424.6 | -296.0 | -405.0 | -92.9 | -129.5 | -54.8 | -44.1 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 272.1 | 253.2 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 198.1 | 199.2 | ||
| Depreciation & Amortization | 13.5 | 13.8 | 13.9 | 14.4 | 14.2 | 14.0 | 15.0 | 13.5 | 13.5 | 13.3 | ||
| Total Operating Expenses | 697.6 | 683.8 | 646.9 | 505.1 | 595.5 | 491.9 | 542.5 | 471.8 | 470.3 | 452.4 | ||
| Operating Income | 131.7 | 368.0 | -16.2 | 18.1 | -105.2 | -76.9 | 48.6 | -43.4 | -116.4 | 213.9 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 111.5 | 111.5 | 122.0 | 95.6 | 24.8 | 1.6 | 11.8 | 33.4 | 29.3 | 12.2 | 8.3 | 5.9 | 2.6 | 1.1 | 1.0 | 1.2 | 2.3 | |
| Interest Expense | 252.6 | 252.6 | 141.9 | 121.2 | 156.0 | 143.0 | 84.5 | 0.0 | 29.3 | 12.2 | 8.3 | 5.9 | 2.6 | 1.1 | 1.0 | 1.2 | 2.3 | |
| Other Expense | -178.4 | -178.4 | -200.5 | -151.3 | -341.9 | -143.5 | -27.2 | 54.2 | 24.7 | -3.0 | 6.2 | 0.1 | -218.9 | 0.0 | -53.1 | -4.0 | -1.2 | |
| IBT | 323.2 | 323.2 | -377.4 | -433.5 | -1,127.0 | -852.1 | -855.6 | -885.3 | -760.7 | -490.9 | -410.1 | -290.1 | -400.6 | -91.9 | -116.6 | -57.6 | -43.0 | |
| Income Tax Expense | 9.4 | 9.4 | -99.2 | 6.7 | 4.2 | 0.7 | 2.7 | 0.9 | 0.8 | -25.6 | -23.4 | -24.9 | -40.2 | -2.7 | -10.6 | -5.8 | 0.5 | |
| Net Income | 313.7 | 313.7 | -278.2 | -440.2 | -1,131.2 | -852.8 | -858.3 | -886.1 | -761.5 | -490.9 | -410.1 | -290.1 | -360.4 | -89.2 | -106.0 | -57.6 | -43.5 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 26.6 | 28.7 | 27.5 | 28.7 | 31.0 | 32.1 | 29.2 | 29.6 | 30.4 | 25.4 | ||
| Interest Expense | 129.3 | 44.4 | 40.2 | 38.6 | 39.0 | 34.4 | 33.3 | 35.3 | 31.3 | 30.9 | ||
| Other Expense | 29.4 | -129.0 | -19.2 | -59.7 | -88.8 | -31.8 | -59.8 | -20.2 | -21.3 | -63.1 | ||
| IBT | 161.1 | 239.0 | -35.4 | -41.6 | -194.0 | -108.7 | -11.2 | -63.6 | -137.7 | 150.7 | ||
| Income Tax Expense | -25.3 | -12.1 | 30.9 | 15.9 | -110.2 | 2.9 | 5.7 | 2.3 | 0.2 | 3.0 | ||
| Net Income | 186.4 | 251.1 | -66.3 | -57.5 | -83.8 | -111.6 | -16.9 | -65.9 | -137.9 | 147.8 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | $-7.57 | $-5.42 | $-4.79 | $-3.45 | $-4.85 | $-1.45 | $-2.11 | $-1.36 | $-1.04 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | $-7.57 | $-5.42 | $-4.79 | $-3.45 | $-4.85 | $-1.45 | $-2.11 | $-1.36 | $-1.04 | |
| Shares Outstanding | 132.2 | 131.0 | 127.7 | 124.9 | 121.7 | 118.5 | 115.0 | 109.3 | 100.6 | 90.6 | 85.6 | 84.0 | 74.3 | 61.6 | 50.3 | 42.4 | 42.0 | |
| Diluted Shares Outstanding | 136.3 | 134.7 | 127.7 | 124.9 | 121.7 | 118.5 | 115.0 | 109.3 | 100.6 | 90.6 | 85.6 | 84.0 | 74.3 | 61.6 | 50.3 | 42.4 | 42.0 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.10 | $1.18 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.10 | $1.15 | ||
| Shares Outstanding | 132.2 | 131.4 | 129.7 | 129.7 | 128.6 | 128.6 | 126.7 | 126.1 | 125.6 | 125.2 | ||
| Diluted Shares Outstanding | 136.3 | 137.3 | 129.7 | 129.7 | 128.6 | 128.6 | 126.7 | 126.1 | 125.6 | 131.3 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 968.5 | 966.4 | 812.7 | 866.4 | 820.0 | 496.6 | 547.2 | 420.1 | 645.4 | 193.6 | 1,281.0 | 881.9 | 53.2 | 51.4 | 70.2 | 74.6 | |
| Short Term Investments | 1,656.2 | 1,728.1 | 1,626.7 | 1,326.0 | 1,615.6 | 1,377.8 | 989.0 | 664.0 | 1,045.3 | 433.2 | 51.4 | 94.6 | 192.7 | 71.4 | 76.2 | 158.5 | |
| Total Cash & ST Investments | 2,624.6 | 2,694.5 | 2,439.4 | 2,192.4 | 2,435.6 | 1,874.4 | 1,536.2 | 1,082.9 | 1,704.5 | 942.6 | 1,332.4 | 976.5 | 350.5 | 226.2 | 146.4 | 233.1 | |
| Accounts Receivable | 309.5 | 405.3 | 327.8 | 238.0 | 198.6 | 102.4 | 43.0 | 18.8 | 34.0 | 23.3 | 8.3 | 39.9 | 4.2 | 0.1 | 1.5 | 14.1 | |
| Inventory | 84.0 | 78.5 | 89.1 | 129.0 | 122.7 | 92.3 | 56.3 | 24.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -142.2 | -226.2 | |
| Other Current Assets | 154.7 | 117.0 | 126.4 | 132.9 | 111.9 | 90.7 | 98.4 | 83.5 | 44.3 | 23.3 | 18.0 | 9.7 | 3.9 | 2.6 | 260.8 | 349.9 | |
| Total Current Assets | 3,172.9 | 3,295.3 | 2,982.7 | 2,692.2 | 2,868.8 | 2,159.8 | 1,733.9 | 1,209.3 | 1,782.8 | 989.2 | 1,358.7 | 1,026.2 | 358.6 | 229.0 | 266.4 | 370.9 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 1,490.2 | 1,113.7 | 1,019.7 | 966.4 | 1,099.9 | 968.5 | 681.9 | 812.7 | 1,033.0 | 657.8 | |
| Short Term Investments | 1,234.4 | 1,743.9 | 1,612.6 | 1,728.1 | 1,680.3 | 1,656.2 | 1,689.4 | 1,626.7 | 1,373.3 | 1,399.7 | |
| Total Cash & ST Investments | 2,724.6 | 2,857.6 | 2,632.2 | 2,694.5 | 2,780.2 | 2,624.6 | 2,371.3 | 2,439.4 | 2,406.3 | 2,057.5 | |
| Accounts Receivable | 964.8 | 567.1 | 418.0 | 405.3 | 353.9 | 309.5 | 321.4 | 327.8 | 325.4 | 220.6 | |
| Inventory | 75.4 | 71.7 | 65.6 | 78.5 | 76.0 | 84.0 | 94.0 | 89.1 | 95.8 | 100.5 | |
| Other Current Assets | 188.0 | 147.3 | 152.4 | 117.0 | 145.4 | 154.7 | 202.0 | 126.4 | 158.0 | 145.5 | |
| Total Current Assets | 3,952.8 | 3,643.7 | 3,268.3 | 3,295.3 | 3,355.4 | 3,172.9 | 2,988.6 | 2,982.7 | 2,985.5 | 2,524.0 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 715.5 | 693.9 | 725.8 | 738.6 | 733.6 | 706.5 | 646.4 | 320.7 | 181.9 | 114.6 | 27.8 | 21.7 | 16.4 | 19.8 | 14.6 | 18.3 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 697.8 | 264.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.4 | |
| Long-Term Investments | 52.1 | 0.0 | 0.0 | -2,559.4 | 0.0 | 0.0 | 14.8 | 44.8 | 30.0 | 9.0 | 251.8 | 279.8 | 45.5 | 38.7 | 0.6 | 3.6 | |
| Other Long-Term Assets | 69.2 | 133.9 | -576.4 | 115.5 | 40.9 | 540.7 | 0.0 | 0.0 | 0.0 | 150.0 | -251.8 | 279.8 | 0.0 | 0.0 | 115.0 | 120.4 | |
| Total Long-Term Assets | 836.8 | 944.7 | 847.2 | 854.1 | 774.5 | 1,247.2 | 661.2 | 365.5 | 211.9 | 273.6 | 27.8 | 53.4 | 61.9 | 58.5 | 15.5 | 22.4 | |
| Total Assets | 4,009.6 | 4,240.0 | 3,829.9 | 3,546.4 | 3,643.3 | 3,407.1 | 2,395.1 | 1,574.8 | 1,994.7 | 1,262.8 | 1,386.5 | 1,079.6 | 420.5 | 287.5 | 281.9 | 393.3 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 693.1 | 692.2 | 695.9 | 693.9 | 703.4 | 715.5 | 718.9 | 725.8 | 729.1 | 736.3 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 697.8 | 0.0 | 0.0 | |
| Long-Term Investments | 53.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 51.6 | -10.4 | -27.3 | |
| Other Long-Term Assets | 53.3 | 125.8 | 142.4 | 133.9 | 146.2 | 121.3 | 116.9 | -3,526.8 | 135.0 | 169.3 | |
| Total Long-Term Assets | 898.9 | 922.3 | 945.6 | 944.7 | 849.6 | 836.8 | 835.8 | 847.2 | 853.6 | 878.3 | |
| Total Assets | 4,851.7 | 4,566.0 | 4,213.8 | 4,240.0 | 4,205.0 | 4,009.6 | 3,824.4 | 3,829.9 | 3,839.1 | 3,402.4 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 74.0 | 88.4 | 55.5 | 98.1 | 73.4 | 52.0 | 49.9 | 59.7 | 28.4 | 54.5 | 16.8 | 15.1 | 5.9 | 4.4 | 5.8 | 20.4 | |
| Short-Term Debt | 103.6 | 154.9 | 96.5 | 42.0 | 321.9 | 329.9 | 303.8 | 62.9 | 11.0 | 11.5 | 6.7 | 5.0 | 2.9 | 4.2 | -62.9 | -11.1 | |
| Other Current Liabilities | 808.6 | 887.5 | 713.0 | 585.7 | 494.1 | 393.8 | 206.5 | 116.3 | 74.2 | 43.7 | 30.0 | 56.4 | 15.3 | 12.5 | 12.8 | 11.1 | |
| Current Liabilities | 1,055.3 | 1,186.3 | 967.8 | 767.9 | 1,191.3 | 1,128.0 | 956.4 | 242.8 | 198.3 | 192.6 | 121.8 | 143.3 | 150.2 | 153.5 | 18.1 | 231.5 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 117.6 | 102.4 | 97.4 | 88.4 | 70.8 | 74.0 | 78.1 | 55.5 | 73.8 | 59.7 | |
| Short-Term Debt | 160.4 | 143.6 | 127.8 | 154.9 | 132.7 | 103.6 | 87.8 | 96.5 | 41.5 | 42.1 | |
| Other Current Liabilities | 1,274.9 | 1,039.8 | 822.3 | 887.5 | 946.2 | 808.6 | 698.9 | 713.0 | 757.3 | 632.2 | |
| Current Liabilities | 1,555.5 | 1,300.8 | 1,075.6 | 1,186.3 | 1,220.7 | 1,055.3 | 941.7 | 967.8 | 949.8 | 769.4 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 2,365.3 | 2,588.5 | 2,586.1 | 1,278.3 | 675.7 | 191.3 | 276.1 | 30.0 | 30.0 | 150.0 | 0.0 | -31.7 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Capital Leases | 239.4 | 271.4 | 284.6 | 303.3 | 321.9 | 329.9 | 303.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 239.4 | 0.0 | 0.0 | 0.0 | -152.4 | -225.1 | 0.0 | -5.4 | -47.4 | -52.5 | 0.0 | 31.7 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 4,012.7 | 4,172.9 | 4,050.5 | 3,704.6 | 3,055.1 | 2,390.8 | 956.4 | 272.8 | 228.3 | 342.6 | 121.8 | 143.3 | 150.2 | 153.5 | 163.9 | 235.0 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 2,612.9 | 2,596.1 | 2,594.4 | 2,588.5 | 2,593.5 | 2,604.6 | 2,596.5 | 2,586.1 | 1,267.5 | 1,272.3 | |
| Capital Leases | 268.2 | 270.5 | 276.1 | 271.4 | 278.2 | 239.4 | 237.8 | 243.1 | 289.2 | 295.5 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 243.1 | 0.0 | 0.0 | |
| Total Liabilities | 4,617.8 | 4,315.4 | 4,098.4 | 4,172.9 | 4,172.7 | 4,012.7 | 4,043.7 | 4,050.5 | 4,004.9 | 3,810.5 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 1.3 | 1.3 | 1.3 | 1.2 | 1.2 | 1.2 | 1.1 | 1.0 | 1.0 | 0.9 | 0.9 | 0.8 | 0.6 | 0.5 | 0.4 | 0.4 | |
| Retained Earnings | -7,092.4 | -7,287.7 | -7,009.6 | -6,569.3 | -5,438.2 | -4,585.4 | -3,727.1 | -2,841.0 | -2,147.7 | -1,656.8 | -1,246.7 | -956.6 | -596.2 | -507.0 | -401.0 | -343.3 | |
| Comprehensive Income | -34.6 | -34.5 | -23.4 | -44.7 | -33.3 | -43.6 | -36.5 | -33.2 | -34.4 | -33.4 | 4.4 | 48.8 | 19.7 | 15.7 | -0.2 | 0.7 | |
| Total Common Equity | -3.1 | 67.1 | -220.6 | -158.2 | 588.2 | 1,016.2 | 1,438.7 | 1,302.0 | 1,766.4 | 920.2 | 1,264.7 | 936.3 | 270.3 | 134.1 | 118.0 | 158.2 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | |
| Retained Earnings | -7,160.4 | -7,411.5 | -7,345.2 | -7,287.7 | -7,204.0 | -7,092.4 | -7,075.5 | -7,009.6 | -6,871.7 | -7,019.5 | |
| Comprehensive Income | -21.8 | -30.0 | -37.5 | -34.5 | -24.8 | -34.6 | -27.0 | -23.4 | -32.3 | -37.1 | |
| Total Common Equity | 233.9 | 250.6 | 115.4 | 67.1 | 32.4 | -3.1 | -219.3 | -220.6 | -165.9 | -408.1 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 2,708.2 | 2,743.4 | 2,682.6 | 1,320.2 | 997.6 | 521.2 | 303.8 | 30.0 | 30.0 | 150.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | -3.1 | 67.1 | -220.6 | -158.2 | 588.2 | 1,016.2 | 1,438.7 | 1,302.0 | 1,766.4 | 920.2 | 1,264.7 | 936.3 | 270.3 | 134.1 | 118.0 | 158.2 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 233.9 | 250.6 | 115.4 | 67.1 | 32.4 | -3.1 | -219.3 | -220.6 | -165.9 | -408.1 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -72.9 | 313.7 | -278.2 | -440.2 | -1,131.2 | -852.8 | -858.3 | -886.1 | -761.5 | -490.9 | -410.1 | -290.1 | -360.4 | -89.2 | -106.0 | -57.6 | -43.5 | |
| Depreciation & Amortization | 65.5 | 55.7 | 56.7 | 97.0 | 85.6 | 89.7 | 74.4 | 54.4 | 6.4 | 13.4 | 15.1 | 19.1 | 11.9 | 10.2 | 9.0 | 5.1 | 4.9 | |
| Stock-Based Compensation | 240.6 | 348.2 | 272.1 | 221.7 | 230.6 | 165.7 | 139.9 | 174.8 | 157.8 | 92.8 | 75.5 | 45.8 | 33.1 | 20.7 | 12.4 | 16.8 | 19.3 | |
| Change Working Capital | -138.3 | -444.8 | -214.1 | 10.8 | -35.6 | -162.8 | -12.7 | 402.4 | 45.1 | -2.9 | 17.2 | 35.1 | -29.4 | -8.1 | -9.0 | -55.9 | -79.6 | |
| Change In Accounts Receivable | -94.1 | -360.0 | -86.6 | -87.9 | -45.6 | -101.8 | -56.2 | -24.2 | 15.2 | -10.7 | -15.0 | 31.6 | -35.7 | -4.1 | 1.4 | 0.0 | 0.0 | |
| Change In Accounts Payable | 149.7 | 75.1 | 91.1 | 80.8 | 191.8 | 88.2 | 117.4 | 36.6 | 15.5 | -4.9 | 10.1 | 1.7 | 8.8 | 1.8 | -1.7 | -3.5 | -3.2 | |
| Change In Inventories | 23.6 | 8.5 | 13.6 | 18.4 | -34.1 | -26.4 | -35.4 | -32.4 | -22.6 | 10.9 | 5.4 | -0.5 | 3.3 | 0.2 | -1.8 | 0.0 | 0.0 | |
| Other Non-cash Items | 396.4 | 253.4 | 261.9 | 214.9 | 309.2 | 174.2 | 95.8 | -12.6 | -6.8 | 2.9 | 1.5 | 1.0 | 221.5 | 0.4 | 0.4 | 1.1 | 3.7 | |
| Cash from Operations | 372.3 | 0.0 | 0.0 | 104.2 | -541.3 | -641.7 | -615.0 | -278.4 | -562.6 | -382.8 | -307.7 | -189.1 | -165.6 | -68.7 | -115.6 | -87.1 | -84.3 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 186.4 | 251.1 | -66.3 | -57.5 | -83.8 | -111.6 | -16.9 | -65.9 | -137.9 | 147.8 | |
| Depreciation & Amortization | 13.5 | 13.8 | 13.9 | 14.4 | -20.5 | 48.7 | 15.0 | 13.5 | 13.5 | 23.5 | |
| Stock-Based Compensation | 0.0 | 108.2 | 111.7 | 56.7 | 91.6 | 45.8 | 89.3 | 45.3 | 42.0 | 63.9 | |
| Change Working Capital | -73.2 | -204.7 | 50.1 | -217.0 | -74.2 | 30.7 | -49.3 | -121.3 | 6.8 | 25.5 | |
| Change In Accounts Receivable | 184.2 | -399.9 | -136.9 | -7.4 | -59.5 | -37.1 | 9.6 | 0.4 | 3.9 | -108.0 | |
| Change In Accounts Payable | 0.0 | 223.5 | 182.1 | -155.7 | -62.1 | 83.6 | 74.5 | -4.9 | -38.7 | 118.7 | |
| Change In Inventories | -13.9 | 5.0 | 11.1 | 6.2 | 0.8 | 5.9 | 6.8 | 0.0 | 12.0 | 4.8 | |
| Other Non-cash Items | 64.0 | 151.1 | 34.6 | 75.5 | -7.8 | 30.0 | 86.1 | 46.4 | 98.9 | 59.4 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -29.8 | 359.4 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -53.4 | -58.7 | -34.3 | -62.2 | -72.1 | -76.4 | -70.4 | -140.2 | -126.9 | -104.2 | -64.6 | -13.0 | -9.0 | -4.0 | -8.3 | -1.3 | -4.7 | |
| Acquisitions | 214.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -82.0 | -17.8 | |
| Investments | -1,786.3 | -1,364.9 | -1,712.0 | -1,882.0 | -1,977.0 | -1,656.1 | -2,025.6 | -2,075.9 | -1,104.0 | -903.5 | -759.3 | -1,033.8 | -977.8 | -364.3 | -277.1 | -293.1 | -390.5 | |
| Sales of Investment | 1,559.0 | 1,802.3 | 1,571.7 | 1,612.3 | 2,231.6 | 1,463.6 | 1,691.7 | 1,775.4 | 1,518.7 | 597.3 | 1,116.5 | 726.9 | 462.9 | 237.8 | 289.0 | 376.4 | 413.0 | |
| Other Investing Activities | -137.1 | 0.0 | 0.0 | -4.4 | -13.2 | -4.4 | -31.2 | 23.0 | -14.8 | 120.0 | -150.0 | -1.5 | -25.0 | 0.0 | -0.2 | 82.0 | 17.8 | |
| Cash from Investing | -285.1 | 0.0 | 0.0 | -336.4 | 169.4 | -273.3 | -435.5 | -417.7 | 272.9 | -290.4 | 142.6 | -321.3 | -548.8 | -130.5 | 3.4 | 82.0 | 17.8 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -23.3 | -12.1 | -14.3 | -9.0 | -9.1 | -4.2 | -8.0 | -13.0 | -15.3 | -17.1 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 225.3 | -10.8 | |
| Investments | -235.9 | -209.7 | -468.8 | -450.5 | -486.7 | -449.6 | -315.6 | -460.1 | -589.2 | -421.5 | |
| Sales of Investment | 222.0 | 723.4 | 332.5 | 524.4 | 443.0 | 423.5 | 357.6 | 405.4 | 363.8 | 432.2 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -225.3 | 6.3 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -240.7 | -10.8 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | -762.1 | 0.0 | 0.0 | -30.0 | 0.0 | -120.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 1,393.9 | 2,743.4 | 60.8 | 1,362.4 | 1,084.8 | 476.4 | 217.4 | 303.8 | 30.0 | 0.0 | 150.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Issuance of Common Stock | 214.3 | 0.0 | 0.0 | 147.5 | 259.4 | 0.0 | 99.5 | 781.9 | 0.0 | 1,161.0 | 14.3 | 585.4 | 723.0 | 173.6 | 86.8 | 0.7 | 3.7 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.5 | -0.3 | -0.6 | -0.4 | -16.0 | -1.4 | -0.4 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 18.4 | 0.0 | 0.0 | 172.1 | 928.5 | 1,247.1 | 895.5 | 71.3 | 68.9 | 84.1 | 164.1 | 31.1 | 29.4 | 28.7 | 7.0 | 0.0 | 0.0 | |
| Cash from Financing | 232.8 | 0.0 | 0.0 | 172.1 | 425.8 | 1,247.1 | 995.0 | 823.2 | 65.5 | 1,124.9 | 177.8 | 616.2 | 736.5 | 200.9 | 93.4 | 0.7 | 3.7 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 2,773.3 | 33.6 | 17.5 | -21.2 | 17.2 | 18.0 | 23.9 | 1.7 | 1,373.6 | -5.3 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 30.9 | 24.8 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 39.2 | 33.1 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 39.2 | 33.1 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 310.7 | 690.2 | 153.8 | -53.7 | 46.4 | 323.1 | -50.6 | 127.0 | -224.2 | 451.7 | 12.7 | 105.7 | 22.0 | 1.8 | -18.8 | -4.4 | -62.9 | |
| Closing Cash Balance | 968.5 | 1,658.8 | 968.7 | 814.9 | 868.6 | 822.2 | 499.0 | 549.6 | 422.6 | 645.4 | 193.6 | 180.9 | 75.2 | 53.2 | 51.4 | 70.2 | 74.6 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 166.0 | 376.9 | 93.6 | 53.6 | -133.8 | 131.3 | 286.6 | -130.8 | -220.3 | 375.2 | |
| Closing Cash Balance | 1,658.8 | 1,492.8 | 1,115.9 | 1,022.2 | 968.7 | 1,102.5 | 968.5 | 681.9 | 812.7 | 1,035.2 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 318.9 | 465.4 | -42.6 | 41.9 | -613.3 | -718.1 | -685.3 | -418.6 | -689.5 | -487.0 | -372.3 | -202.1 | -174.6 | -72.7 | -124.0 | -88.4 | -89.1 | |
| Real Free Cash Flow | 78.3 | 117.1 | -314.7 | -179.7 | -844.0 | -883.8 | -825.2 | -593.4 | -847.3 | -579.8 | -447.8 | -247.9 | -207.7 | -93.4 | -136.3 | -105.2 | -108.4 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 140.3 | 313.0 | 139.4 | -127.3 | -103.8 | 39.5 | 116.1 | -94.5 | -45.1 | 342.3 | |
| Real Free Cash Flow | 140.3 | 204.8 | 27.8 | -184.0 | -195.4 | -6.3 | 26.9 | -139.8 | -87.1 | 278.4 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 135.6 | -9.1 | -1.4 |
| P/S | 11.5 | 62.6 | 9.4 |
| P/B | 181.9 | -207.7 | 5.2 |
| P/FCF | 225.4 | -25.1 | -1.5 |
| Market cap | $59.1 | $27.9 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 14 % | 0 % |
| Debt to Income | 883.9 % | -37.1 % | 0 % |
| Debt to Free cash flow | 1469.1 % | -253.5 % | 0 % |
| Interest expense percentage | 50.4 % | -9.2 % | 44.7 % |
| Current ratio | 2.5 | 6.2 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 134.1 % | 22.3 % | 0 % |
| ROA | 6.5 % | -22.8 % | 0 % |
| CapEx to Revenue | 1.6 % | 37.8 % | 0 % |
| RaD to Revenue | 0 % | 275.7 % | 0 % |
| ROEM | 1,665,442.6 | 302876.5 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 81.7 % | 93.4 % | 68.7 % |
| Operating margin | 13.5 % | -348.4 % | 35.5 % |
| Net margin | 8.4 % | -335.1 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 136.3 mil | 92.7 mil |
| Employee count | 2.2 tis | 0.7 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
